«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第6期

页码:

731-735,740

栏目:

综述

出版日期:

2016-07-05

文章信息/Info

Title:

Research progress of anticoagulants in atrial fibrillation

作者:

罗文榕¹; 张 晨¹; 赵志敬²

（第四军医大学:1.学员旅，2.西京医院心血管内科，陕西 西安 710032）

Author(s):

LUO Wen-rong¹;  ZHANG Chen¹;  ZHAO Zhi-jing²

(1.Cadet Brigade, 2.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:

心房颤动; 华法林; 新型口服靶向抗凝药

Keywords:

atrial fibrillation;  warfarin;  target-specific oral anticoagulants

分类号:

R541.7

DOI:

-

文献标识码:

A

摘要:

大部分心房颤动（AF）患者都需要接受抗凝治疗，2014年美国心脏学会更新的AF抗凝指南将新型口服靶向抗凝药划入选择的范畴。本文就AF抗凝药物的最新研究进展作一介绍。

Abstract:

Most patients with atrial fibrillation (AF) will be treated with anticoagulants. In 2004, the American Heart Association updated the anticoagulant guidelines for AF and classified the target-specific oral anticoagulants as a new alternative. This review is to introduce the latest research progress of anticoagulants in AF.

参考文献/References

[1]Rosamond W,Flegal K,Furie K,et al.Heart disease and stroke statistics--2008 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2008,117(4):e25-e146.
[2]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130(23):2071-104.
[3]The ESC Committee for Practice Guidelines(CPG)[J].Eur Heart J,2013,34(10):703-704.
[4]Olesen JB,Torp-Pedersen C,Hansen ML,et al.The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1:a nationwide cohort study[J].Thromb Haemost,2012,107(6):1172-1179.
[5]Ayez N,van der Stok EP,de Wilt H,et al.Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectablecolorectal liver metastases:the CHARISMA randomized multicenter clinical trial[J].BMC Cancer,2015,15:180.
[6]Connolly S,Yusuf S,Budaj A,et al.Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascularevents[J].Am Heart J,2006,151(6):1187-1193.
[7]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21):e1-e76.
[8]Hart RG,Benavente O,McBride R,et al.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:a meta-analysis[J].Ann Intern Med,1999,131:492-501.
[9]Mant J,Hobbs FD,Fletcher K,et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial[J].Lancet,2007,370(9586):493-503.
[10]Jun M,James MT,Manns BJ,et al.The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarintreatment: population based observational study[J].BMJ,2015,350:h246.
[11]Tanaka-Esposito C,Chung MK.Selecting antithrombotic therapy for patients with atrial fibrillation[J].Cleve Clin J Med,2015,82(1):49-63.
[12]Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med. Med,2011,365(11):981-992.
[13]Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation[J].N Engl J Med,2011,364(9):806-17.
[14]Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med.Med,2011,365(11):981-992.
[15]Perzborn E,Roehrig S,Straub A,et al.The discovery and development of rivaroxaban,an oral,direct factor Xa inhibitor[J].Nat Rev Drug Discov,2011,10(1):61-75.
[16]Patel MR,Mahaffey KW,Garg J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10):883-891.
[17]Rondina M.ACP Journal Club:in nonvalvular atrial fibrillation,effects of rivaroxaban compared with warfarin did not differ by patient age[J].Ann Intern Med,2014,161(10):JC5.
[18]Mendell J,Lee F,Chen S,et al.The effects of the antiplatelet agents,aspirin and naproxen,on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban,a direct factor Xa inhibitor[J].Cardiovasc Pharmacol,2013,62(2):212-221.
[19]Zahir H,Matsushima N,Halim AB,et al.Edoxaban administration following enoxaparin: a pharmacodynamic,pharmacokinetic, and tolerability assessment in human subjects[J].Thromb Haemost,2012,108(1):166-175.
[20]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[21]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[22]Krejczy M,Harenberg J,Wehling M,et al.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared towarfarin in Germany[J].Biomed Res Int,2015,2015:876923.
[23]Senoo K,Lane DA,Lip GY,et al.Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation[J].Curr Probl Cardiol,2014,39(9):319-344.

备注/Memo

备注/Memo:

收稿日期：2015-07-22.
通讯作者：赵志敬，副教授，主要从事血管内超声基础和临床研究Email：zhaozhj@fmmu.edu.cn
作者简介：罗文榕，本科生Email：3032012192@student.fmmu.edu.cn

常用功能

更新日期/Last Update: 2016-07-10